ABSTRACT
Objective:
Investigate the efficacy and safety of Yao Medicine in the treatment of
advanced non-small-cell lung carcinoma, and explore the best therapeutic
measure for clinical benefit. Methods: From July 2020 to July 2022, 84 patients with advanced non-small-cell lung
carcinoma were selected and randomly divided into the Observation Group and control group, and the control
group was treated with routine Western medicine, with 42 cases in each group. The activity of daily living
(ADL) was assessed before and after treatment, meanwhile, the self-rating depression scale (SDS) and self-rating
anxiety SAS (SAS) were used to assess the improvement of a bad
mood, and quality of life SF-36 was used to assess the quality of life, to
judge the efficacy and safety. Results: The effective rate of observation group
was 91.67%. The effective rate of the control
group was 76.19%. The effective rate of the observation group was significantly
higher than that of the control group (P < 0.05). There were no significant differences in the
scores of SDS, SAS and quality of life between the two groups before treatment
(P > 0.05), and after treatment, the scores of SDS, SAS and quality of life
in the two groups were compared with those in the control group (P > 0.05),
the scores of VAS, SDS and SAS decreased significantly, while ESCV, angle of
straight leg elevation, ADL, physiological score, emotional score, social score
and health status score increased significantly, the difference was
statistically significant (P < 0.05). Conclusion: Yao Medicine can improve the
psychosomatic symptoms of patients with advanced non-small-cell lung carcinoma
better, with better efficacy and higher safety.